TRANSCENTA-B 06628Hong Kong Stock Exchange

0.8104.71%( -0.040 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
TRANSCENTA-B (06628) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2021-09-29
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG9005B1041

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)8.72M108/112
Net Profit (Last FY)-238.90M81/125
ROE (Last FY)-32.96%90/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
Xueming Qian Executive Director
Li Xu Non-Executive Director
Han Sen Xu Non-Executive Director
Jiasong Tang Independent Non-Executive Director
Helen Wei Chen Independent Non-Executive Director
Genhong Cheng Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-08-28.

About this page

This page shows TRANSCENTA-B (06628) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.